Abstract
Chemotherapy has remained the major treatment modality for patients with metastatic or recurrent colorectal carcinoma. The chemotherapeutic agent, 5-fluorouracil (FUra), has been the “standard” therapy for a number of years. The objective response rate for this single agent has been disappointing with most series reporting response rates between 12 and 20%. Recent studies involving intracellular pharmacokinetics of FUra have provided information concerning mechanisms which lead to cellular resistance to the active metabolite, FdUMP, which binds to intracellular thymidylate synthetase (TS). A number of recent studies have now been performed which suggest that increased levels of intracellular reduced folate analogs can overcome intracellular drug resistance to FdUMP.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.